FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average b	urden				
houre por rocponeo	0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 37	I A 44 C	D 1		2 Iames	NIama a	nd Tiples	on Tuodin -	Cramb ol	5 1	Relationshi	n of Reporti	ng Person(s)	to Icener	
Name and Address of Reporting Person – OMara Patrick J.			2. Issuer Name and Ticker or Trading Symbol CymaBay Therapeutics, Inc. [CBAY]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Middle) C/O CYMABAY THERAPEUTICS, INC., 7999 GATEWAY BLVD., SUITE 130				3. Date of Earliest Transaction (Month/Day/Year) 01/26/2016					Х	X Officer (give title below) Other (specify below) VP, Business Development				
(Street) NEWARK, CA 94560			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu					s Acquired	lired, Disposed of, or Beneficially Owned					
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8	(A) or Disposed of				Securities Beneficially ving Reported		Ownership Form:	7. Nature of Indirect Beneficial Ownership	
						Code	v A	(A) or (D)	Price				r Indirect (Instr. 4) I) Instr. 4)	
			T-II- II I	Di4	G	• •	form di	ed in this for	•	id OMB co		iber.		
Security	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, i	4. Transact Code	tion of Der Sec (A) Dis	arrants, on Number rivative curities equired to or sposed of	form di ired, Dispo ptions, co	splays a curresed of, or Bendayertible securerisable and Date	eficially O	wned and of ing	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported	Ownersh Form of Derivativ Security: Direct (D or Indirect	(Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, i	4. Transact Code	5. Notion of Den According (A) Dis (D)	arrants, on Number rivative curities quired or sposed of str. 3, 4,	form di ired, Dispo poptions, coi 6. Date Ex Expiration (Month/D:	sed of, or Benevertible securercisable and Date hy/Year)	reficially Orities) 7. Title a Amount Underlyin Securitie (Instr. 3 a	wned and of ing is and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following	Ownersh Form of Derivativ Security: Direct (D or Indirect	of Indire Benefici Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, i	4. Transact Code	tion of Der	arrants, on Number rivative curities quired or sposed of str. 3, 4,	form di ired, Dispo options, cor 6. Date Ex Expiration (Month/Di	sed of, or Benevertible securercisable and Date hy/Year)	7. Title a Amount Underlyi Securitie	wned and of ing es and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	Ownersh Form of Derivativ Security: Direct (D or Indirects) (I)	of Indire Benefici Ownersh (Instr. 4)

Reporting Owner Name / Address	Relationships				
reporting 6 wher runner, runness	Director	10% Owner	Officer	Other	
OMara Patrick J. C/O CYMABAY THERAPEUTICS, INC. 7999 GATEWAY BLVD., SUITE 130 NEWARK, CA 94560			VP, Business Development		

Signatures

/s/ Sujal Shah, by power of attorney	01/28/2016
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares monthly thereafter over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.